
Dec 30 (Reuters) - InflaRx NV IF0G.F:
INFLARX PROVIDES UPDATE ON PHASE 3 DATA ANALYSES FOR VILOBELIMAB IN PYODERMA GANGRENOSUM
INFLARX NV - PHASE 3 TRIAL OF VILOBELIMAB TERMINATED DUE TO FUTILITY
INFLARX NV: ANTICIPATES MEETING WITH FDA TO DETERMINE A POTENTIAL DEVELOPMENT PATH FORWARD IN PG
INFLARX: SUBSEQUENT POST-HOC ANALYSES SUGGEST POSITIVE TREND IN FAVOR OF VILOBELIMAB, WITH SIGNALS INDICATING POTENTIALLY CONSISTENT TREATMENT EFFECT